Pharmacodynamics and pharmacokinetics of iganidipine

Cardiovascular Drug Reviews

Volumn 14, Issue 3, 1996, Pages 213-230

  Yamada, Shizuo ^a   Kimura, Ryohei ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Antihypertensive drug; Arterial injury protection; Calcium antagonist; Iganidipine; Nephroprotection; Pharmacokinetics; Receptor occupancy; Toxicology; Vascular selectivity

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; IGANIDIPINE; ISRADIPINE; NICARDIPINE; NITRENDIPINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTERY CONSTRICTION; ARTERY INJURY; BIOACCUMULATION; BRAIN ARTERY; BRAIN CORTEX; CHROMAFFIN CELL; CONTROLLED STUDY; CORONARY ARTERY; DISSOCIATION CONSTANT; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG RECEPTOR BINDING; FEMALE; GLOMERULOSCLEROSIS; HEART MUSCLE FIBER MEMBRANE; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY BLOOD VESSEL; KIDNEY FUNCTION; KIDNEY INJURY; LIVER METABOLISM; MALE; MEAN ARTERIAL PRESSURE; MESENTERIC ARTERY; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; VOMITING; WEIGHT GAIN;

EID: 0029828153     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.1996.tb00227.x     Document Type: Review

References (49)

1. Abraham NG, Pinto A, Mullane KM, et al. Presence of cytochrome P-450-dependent monooxygenase in intimai cells of hog aorta. Hypertension 1985;7.899-904.
2. 3H]nitrendipine, a potent calcium antagonist. Arzneimeittelforschung/Drug Res 1981;31:2064-2067.
3. Bolger CT, Gengo PT, Luckowski EM, et al. High affinity binding to a calcium channel antagonists to smooth and cardiac muscle. Biochem Biophys Res Commun 1982;104:1604-1609.
4. 2+ channel antagonists. Trends Pharmacol Sci 1992;13: 256-262
5. Dahl LK, Schackow E. Effects of chronic excess salt ingestion; experimental hypertension in the rat Can Med Assoc J 1964;90:155-160.
6. 3H]-nitrendipine to receptors for calcium channel antagonists in the heart, cerebral cortex, and ileum of rats. Life Sci 1982;30:2191-2202.
7. Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle. Ann Rev Pharmacol Toxicol 1977,17:149-166.
8. Foster TS, Hamann SR, Richards VR, et al Nifedipine kinetics and bioavailability after single intravenous and oral doses in manual subjects. J Clin Pharmacol 1983;23:161-170.
9. Godfraind T, Miller R, Wibo M. Calcium antagonism and calcium entry blockade. Pharmacol Rev 1986; 38:321-416.
10. 3H]nitrendipine-labeled calcium channels discriminate inorganic calcium agonists and antagonists. Proc Natl Acad Sci USA 1982;79:3656-3660.
11. Graefe KH, Ziegler R, Wingender R, et al. Plasma concentration-response relationships for some cardiovascular effects of dihydropyridines in healthy subjects. Clin Pharmacol Ther 1988,43:16-22
12. Higuchi S, Shiobara Y. Comparative pharmacokinetics of nicardipine hydrochloride, a new vasodilator, in various species. Xenobiotica 1980;10:447-454.
13. Hofmann F, Nastainczyk W, Rohrkasten A, et al. Regulation of the L-type calcium channel. Trends Pharmacol Sci 1987;8:393-398.
14. Imagawa J, Satoh K, Taira N. Coronary vasodilator and cardiac effects of NKY-722, a novel hydrophilic 1,4-dihydropyridine derivative, in the blood-perfused dog heart. Cardiovasc Drug Ther 1989;3:81-90.
15. Jaffe D, Sutherland LE, Barken DM, et al. Effects of chronic excess ingestion. Morphologic findings in kidneys of rats with differing genetic susceptibilities to hypertension. Arch Pathol 1970;90:1-16.
16. Kanda M, Shirahase H, Kurahashi K, et al. Effects of the novel water-soluble calcium antagonist (±)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride on the responses of isolated canine arteries. Arzneimeittelforschung/ Drug Res 1995;45:831-835.
17. Kanda M, Shirahase H, Wada K, et al. Effects of the novel water-soluble calcium antagonist (±)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride on the endothelium-independent and endothelium-dependent contraction in isolated canine cerebral arteries. Arzneimeittelforschung/Drug Res 1996;46:663-666.
18. Kelly JG, O'Malley K. Clinical pharmacokinetics of calcium antagonists. Clin Pharmacokinet 1992;23: 1-10.
19. 3H]PN 200-110 binding to dihydropyridine receptors associated with channels in rat cerebral cortex and heart. Life Sci 1984,35:721-732.
20. 2 attenuates ischemic acute renal failure in the rat. Am J Physiol 1984;247:F714-F717.
21. Meredith PA, Elliott HL. Clinical pharmacokinetics of amlodipine Clin Pharmacokinet 1992;22:22-31.
22. Mikami A, Imoto K, Tanabe T, et al. Primary structure and functional expression of the cardiac dihydropyridine-sensitive calcium channel. Nature 1989;340:230-233.
23. 2, and prostacyclin. Pharmacol Rev 1979;30:293-331.
24. Nagaoka A, Shibota M, Hamajo K, et al. Effects of a new dihydropyridine derivative, CV-4093-2HCl, on renal hemodynamics in spontaneously hypertensive rats. Jpn J Pharmacol 1989;51:25-35.
25. 2 infusion on the course of postischemic acute renal failure Long-term studies in chronically instrumented conscious dogs. Renal Physiol 1985;8:159-168.
26. 2+ antagonist, in spontaneously hypertensive rats. Eur J Pharmacol 1996;287:191-196.
27. 2+ antagonist in bovine cultured adrenal chromaffin cells. Br J Pharmacol 1991;103:1889-1892.
28. Oizumi T, Nishino H, Miyake S, et al. Hemodynamic changes following long-term administration of CS-905, a novel dihydropyridine calcium channel blocker, in conscious SHR. Jpn J Pharmacol 1990;54: 1-6.
29. Osumi S, Morishita S, Wada K, et al. Antihypertensive effects of NKY-722, a new water-soluble 1,4-dihydropyridine derivative, on conscious spontaneously hypertensive rats. Tohoku J Exp Med 1988;155: 205-206.
30. 2+ antagonist. Eur J Pharmacol 1990;183 1323-1324.
31. Rhodes DG, Sarmiento JG, Herbette LG, et al. Kinetics of binding of membrane-active drugs to receptor sites. Mol Pharmacol 1985;27:612-623.
32. Shepro D, Dunham B. Endothelial cell metabolism of biogenic amines. Ann Rev Physiol 1986;48:335-345.
33. 2+ channel antagonist, in canine mesenteric arteries. Eur J Pharmacol 1991;196:197-199.
34. 2+ antagonist, on KCl-induced contraction in isolated canine mesenteric arteries. J Pharmacol Exp Ther 1991;258:676-680.
35. Shirahase H, Uehara Y, Wada K, et al. Protective effect of the calcium antagonist NKY-722 against renal and arterial injuries in Dahl salt-sensitive rats. J Hypertension 1994;12:137-144.
36. Stephenson RP. A modification of receptor theory. Br J Pharmacol Chemother 1956,11:379-393.
37. Takahashi H, Nakamura S, Shirahase H, et al. Effects of a novel dihydropyridine derivative calcium channel blocker, NKY-722, on regional hemodynamics, and its influences on the effects of endothelin in anesthetized rats. Hypertens Res 1994;17:29-34.
38. Takata Y, Kato H. Comparative study on acute antihypertensive effects and pharmacokinetics of nisoldipine, nifedipine, nimodipine, and nicardipine administered orally to conscious renal hypertensive dogs. Arzneimeittelforschung/Drug Res 1986;36:1464-1471.
39. Tanabe T, Takeshima H, Mikami A, et al. Primary structure of the receptor for calcium channel blockers from skeletal muscle. Nature 1987;328-313-318.
40. 2+ channels. Trends Pharmacol Sci 1991;12.349-354.
41. Uchida S, Yamada S, Ohkura T, et al. The receptor occupation and plasma concentration of NKY-722, a water-soluble dihydropyndine-type calcium antagonist, in spontaneously hypertensive rats. Br J Pharmacol 1995;114:217-223.
42. Usui H, Fujiwara M, Shirahase H, et al. Endothelium-dependent vasoactivation of the canine cerebral artery by cerebrospinal fluid obtained from patients who had suffered a subarachnoid hemorrhage In: Nobin A, et al., eds. Neuronal Messengers in Vascular Function. Elsevier Science Publishers, 1987.
43. Wada K, Nakamura S, Morishita S, et al. Antihypertensive effect of the novel water-soluble calcium antagonist (±)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate dihydrochloride in rats Arzneimetttelforschung/Drug Res 1994;44: 1112-1116.
44. Watanabe H, Nishio M, Miura M, et al. L-type Ca channel block by highly hydrophilic dihydropyridines in single ventricular cells of guinea pig hearts. J Mol Cell Cardiol 1995;27:1271-1279.
45. Wu WH, Henderson BM, Lane R, et al. Relationship between the pharmacokinetic and pharmacodynamic profile of nilvadipine in the dog. Drug Metab Dispos 1988;16:222-227.
46. 3H]PN 200-110 in coronary artery. J Pharmacol Exp Ther 1990;252:327-332.
47. Yamada S, Matsuoka Y, Kato Y, et al. A sustained occupancy in vivo of cardiovascular calcium antagonist receptors by mepirodipine and its relation to pharmacodynamic effect in spontaneously hypertensive rats. J Pharmacol Exp Ther 1992;262:589-594.
48. Yamada S, Sugimoto N, Uchida S, et al. Pharmacokinetics of amlodipine and its occupancy of calcium antagonist receptors. J Cardiovasc Pharmacol 1994;23:466-472.
49. Yanagisawa M, Kurihara H, Kimura S. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411-415.